CureDuchenne provided early and significant funding to Capricor Therapeutics for their Duchenne program, and we are pleased to share their latest updates. One-year results from their HOPE-2 open label extension study in non-ambulant Duchenne showed significant improvements on the Performance of Upper Limb (PUL version 2.0) for individuals receiving CAP-1002, a type of progenitor cell derived from cardiospheres. This data builds on the results of the HOPE-2 study, which met its primary endpoint by demonstrating statistically significant improvements in upper limb function at 12 months, and indicates CAP-1002 continues to be a safe and promising experimental therapeutic.
The HOPE-2 open label extension study remains ongoing, and all participants will continue to be monitored for safety and functional performance.
Capricor’s Phase 3 trial, HOPE-3, is currently recruiting. NCT05126758
Read Capricor’s full press release below.